Purpose of review Most hypertension devices have been designed to interrupt or modify the sympathetic nervous system, which seems to be unbalanced in hypertension. Carotid baroreceptors play a pivotal role in maintaining adrenergic balance via a direct feedback interface and would be an exceptional target for intervention. The purpose of this review is to define the role of the baroreceptor in hypertension, to examine device-based therapies targeting the baroreflex and to explore future promises of endovascular baroreflex amplification (EBA). Recent findings In the last two decades, two therapeutic strategies targeting the carotid baroreceptor have evolved: baroreflex activation therapy (BAT) and EBA. Both therapies enhance baroreceptor activity, either directly by electrical stimulation or indirectly by changing the geometric shape of the carotid sinus and increasing pulsatile wall strain. Summary By showing a significant, sympathetic inhibition-mediated effect on blood pressure, BAT has laid the foundation for baroreflex-targeting therapies for resistant hypertension. EBA is a less invasive therapy with promising first-in-man study results. Ongoing randomized sham-controlled trials are needed to better understand efficacy, durability, and long-term safety and define phenotypes that may most benefit from this treatment.
Digital Commons Citation
van Kleef, Monique E. A. M.; Bates, Mark C.; and Spiering, Wilko, "Endovascular Baroreflex Amplification for Resistant Hypertension" (2018). Clinical and Translational Science Institute. 851.
van Kleef MEAM, Bates MC, Spiering W. Endovascular Baroreflex Amplification for Resistant Hypertension. Current Hypertension Reports. 2018;20(5). doi:10.1007/s11906-018-0840-8